Morgan Stanley assumed coverage of CG Oncology (CGON) with an Overweight rating and $55 price target Morgan Stanley sees a competitive profile for cretostimogene in bladder cancer, with indication expansion potential beyond high-risk Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer. In addition to strong data, the firm thinks the familiarity of the same route of administration as standard-of-care BCG therapy should help encourage urologists to prescribe cretostimogene once approved.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- Buy Rating for CG Oncology: Promising Market Position and Upside Potential of Cretostimogene in NMIBC Treatment
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
- CG Oncology Amends Key Executive Employment Agreements
- Pfizer study impact on CG Oncology to be minimal, says H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue